As the availability and utilization of ultra-high-cost, long-term specialty products such as GLP-1s and cell and gene therapies grows, HR decision-makers and pharmacy consultants must embrace a more value-oriented mindset where they can.
Bridget Mulvenna
Advertisement
Articles by Bridget Mulvenna
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Pfizer’s Stock Reacts to Decreases in 2026 Revenue Projections in Full-Year 2026 Guidance Release
2
FDA Approves GSK's Exdensur as Twice-Yearly Add-On Therapy for Severe Asthma
3
Four Republicans Break with House GOP to Force Vote on Extending ACA Tax Credits
4
Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience
5